COOPERS NILVAX COMBINATION 5-IN-1 VACCINE AND BROAD SPECTRUM INJECTABLE ANTHELMINTIC אוסטרליה - אנגלית - APVMA (Australian Pesticides and Veterinary Medicines Authority)

coopers nilvax combination 5-in-1 vaccine and broad spectrum injectable anthelmintic

intervet australia pty limited - levamisole; clostridium chauvoei - killed; clostridium novyi type b - killed; clostridium chauvoei - toxoid; clostridium novyi type b - toxoid; clostridium perfringens type d toxoid; clostridium septicum - toxoid; clostridium tetani - toxoid; thiomersal - misc. vaccines or anti sera - levamisole anthelmintic active 68.0 g/l; clostridium chauvoei - killed vaccine-microbial active 0.0 p; clostridium novyi type b - killed vaccine-microbial active 0.0 p; clostridium chauvoei - toxoid vaccine-toxoid active 0.0 p; clostridium novyi type b - toxoid vaccine-toxoid active 0.0 p; clostridium perfringens type d toxoid vaccine-toxoid active 0.0 p; clostridium septicum - toxoid vaccine-toxoid active 0.0 p; clostridium tetani - toxoid vaccine-toxoid active 0.0 p; thiomersal mercury other 0.15 mg/ml - immunotherapy - sheep - not lambs | ewe | ovine | ram - barber's pole worm - haemonchus spp. | black disease | black scour worm - trichostrongylus spp. | blackleg | enterotoxaemia (pulpy kidney) | intestinal threadworm-strongyloides spp. | large bowel worm - oesophagostomum spp. | lungworm - dictyocaulus spp. | malignant oedema | small brown stomach worm-ostertagia spp. | small intestinal worm - cooperia spp. | stomach hair worm | tetanus | thin necked intestinal worm | vaccine | clostridium perfringens type d | equine rotavirus | hair worm | intestinal hair worm | pole worm | small hair worm | teladorsagia | tetanus vaccination

Netvax האיחוד האירופי - אנגלית - EMA (European Medicines Agency)

netvax

intervet international bv - clostridium-perfringens-type-a alpha toxoid - immunologicals for aves - chicken - for the active immunisation of chickens to provide passive immunisation against necrotic enteritis to their progeny, during the laying period.to reduce mortality and the incidence and severity of lesions caused by clostridium-perfringens-type-a-induced necrotic enteritis. efficacy was demonstrated by challenge of chicks approximately three weeks after hatching.the onset of passive transfer of immunity: 6 weeks following completion of the vaccination procedure.the duration of passive transfer of immunity: 51 weeks following completion of the vaccination procedure.

Porcilis ColiClos האיחוד האירופי - אנגלית - EMA (European Medicines Agency)

porcilis coliclos

intervet international bv - clostridium perfringens type c / escherichia coli f4ab / e. coli f4ac / e. coli f5 / e. coli f6 / e. coli lt - immunologicals - pigs - for the passive immunisation of progeny by active immunisation of sows and gilts to reduce mortality and clinical signs during the first days of life, caused by those escherichia coli strains which express the adhesins f4ab (k88ab), f4ac (k88ac), f5 (k99) or f6 (987p) and caused by clostridium perfringens type c.,

CLOSTRIDIUM PERFRINGENS TYPE D TOXOID (INACTIVATED) אוסטרליה - אנגלית - APVMA (Australian Pesticides and Veterinary Medicines Authority)

clostridium perfringens type d toxoid (inactivated)

virbac (australia) pty ltd - clostridium perfringens type d toxoid - unknown - clostridium perfringens type d toxoid vaccine-toxoid active 0.0 - active constituent

Enteroporc Coli AC האיחוד האירופי - אנגלית - EMA (European Medicines Agency)

enteroporc coli ac

ceva santé animale - clostridium perfringens type c, beta1 toxoid / clostridium perfringens, type a, alpha toxoid / clostridium perfringens, type a, beta2 toxoid / escherichia coli, fimbrial adhesin f4ab / escherichia coli, fimbrial adhesin f4ac / escherichia coli, fimbrial adhesin f5 / escherichia coli, fimbrial adhesin f6 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - pigs - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:-           clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6-           clinical signs (diarrhoea during the first days of life) associated with clostridium perfringens type a expressing alpha and beta 2 toxins-           clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by clostridium perfringens type c expressing beta1 toxin

Suiseng Each 2 mL (dose) contains: E. coli (F4ab fimbrial adhesin) E. coli (F4ac fimbrial adhesin) E. coli (F5 fimbrial adhesin) E. coli (F6 fimbrial adhesin) LT Enterotoxoid of E.coli B-Toxoid Clostridium perfringens, Type C á-Toxoid Clostridium novyi $5% ER * »78% ER70 59% ER30 80% ER25 5% ER 70 5% ERS >50% ER 120 Suspension for Injection (IM) פיליפינים - אנגלית - FDA (Food And Drug Administration)

suiseng each 2 ml (dose) contains: e. coli (f4ab fimbrial adhesin) e. coli (f4ac fimbrial adhesin) e. coli (f5 fimbrial adhesin) e. coli (f6 fimbrial adhesin) lt enterotoxoid of e.coli b-toxoid clostridium perfringens, type c á-toxoid clostridium novyi $5% er * »78% er70 59% er30 80% er25 5% er 70 5% ers >50% er 120 suspension for injection (im)

hipra philippines, inc.; distributor: hipra philippines, inc. - escherichia coli fimbrial adhesins , e. coli lt enterotoxoid , clostridium perfringens b-toxoid , c. novyi type b a-toxoid vaccine (vet.) - suspension for injection (im) - each 2 ml (dose) contains: e. coli (f4ab fimbrial adhesin) e. coli (f4ac fimbrial adhesin) e. coli (f5 fimbrial adhesin) e. coli (f6 fimbrial adhesin) lt enterotoxoid of e.coli b-toxoid clostridium perfringens, type c á-toxoid clostridium novyi $5% er * »78% er70 59% er30 80% er25 5% er 70 5% ers >50% er 120

Suiseng Diff/A האיחוד האירופי - אנגלית - EMA (European Medicines Agency)

suiseng diff/a

laboratorios hipra, s.a. - clostridioides difficile toxoid a, clostridioides difficile toxoid b, clostridium perfringens, type a, alpha toxoid - immunologicals for suidae, inactivated bacterial vaccines for pigs, clostridium - pigs - for the passive immunisation of neonatal piglets by means of the active immunisation of breeding sows and gilts:- to prevent mortality and reduce clinical signs and macroscopic lesions caused by clostridioides difficile toxins a and b.- to reduce clinical signs and macroscopic lesions caused by clostridium perfringens type a, alpha toxin.

Toxipra Plus Formulation: Each 2 mL (dose) contains: Clostridium perfringens (Type B, C, and D) B Toxoid .................... > 10 IU/mL Clostridium perfringens (Type B, C, and D) e Toxoid............. >3.5 IU/mL Clostridium novyi (Type B) a Toxoid......... > 2.5 IU/mL Clostridium septicum a Toxoid ............. Clostridium chauvoei ............ ........... 100 % Protection Clostridium tetani Toxoid........... > 2.5 IU/mL Suspension for Injection (IM/SC) פיליפינים - אנגלית - FDA (Food And Drug Administration)

toxipra plus formulation: each 2 ml (dose) contains: clostridium perfringens (type b, c, and d) b toxoid .................... > 10 iu/ml clostridium perfringens (type b, c, and d) e toxoid............. >3.5 iu/ml clostridium novyi (type b) a toxoid......... > 2.5 iu/ml clostridium septicum a toxoid ............. clostridium chauvoei ............ ........... 100 % protection clostridium tetani toxoid........... > 2.5 iu/ml suspension for injection (im/sc)

hipra philippines, inc.; distributor: hipra philippines, inc. - inactivated clostridium perfringens b and e , clostridium novyi a , clostridium septicum a , clostridium chauvoei , clostridium tetani vaccine (vet.) - suspension for injection (im/sc) - formulation: each 2 ml (dose) contains: clostridium perfringens (type b, c, and d) b toxoid .................... > 10 iu/ml clostridium perfringens (type b, c, and d) e toxoid............. >3.5 iu/ml clostridium novyi (type b) a toxoid......... > 2.5 iu/ml clostridium septicum a toxoid ............. clostridium chauvoei ............ ........... 100 % protection clostridium tetani toxoid........... > 2.5 iu/ml

Toxipra Plus Formulation: Each 2 mL[dose) contains: Clostridium perfringens (Type B, C and D) b Toxoid ->10 IU C. perfringens (Type B, C and D) e Toxoid-5IU Clostridium novyi (Type B) e Toxoid->5 IU Clostridium septicum a Toxoid-->5 IU Clostridium chauvoei- 100% protection Clostridium tetani-->5 IU Suspension For Injection (IM/SC) פיליפינים - אנגלית - FDA (Food And Drug Administration)

toxipra plus formulation: each 2 ml[dose) contains: clostridium perfringens (type b, c and d) b toxoid ->10 iu c. perfringens (type b, c and d) e toxoid-5iu clostridium novyi (type b) e toxoid->5 iu clostridium septicum a toxoid-->5 iu clostridium chauvoei- 100% protection clostridium tetani-->5 iu suspension for injection (im/sc)

hipra philippines inc.; distributor: hipra philippines inc. - inactivated clostridium perfringens b and € , clostridium novyi a , clostridium septicum a , clostridium chauvoei , clostridium tetani vaccine (vet.) - suspension for injection (im/sc) - formulation: each 2 ml[dose) contains: clostridium perfringens (type b, c and d) b toxoid ->10 iu c. perfringens (type b, c and d) e toxoid-5iu clostridium novyi (type b) e toxoid->5 iu clostridium septicum a toxoid-->5 iu clostridium chauvoei- 100% protection clostridium tetani-->5 iu

Suiseng Each 2 mL (dose) contains: Escherichia coli Fimbrial Adhesin F4ab F4ac F5 F6 %65% ER60 278% ER70 279% ER 50 >80% ER35 >55% ER 70 >35% ER25 >50% ER120 E. coli LT Enterotoxoid Clotridium perfringens (Type C) BToxoid Clostridium novyi (Type B) a Toxoid % ERx: Percentage of immunized rabbits with enzyme immunoassay response. Suspension for Injection (IM) פיליפינים - אנגלית - FDA (Food And Drug Administration)

suiseng each 2 ml (dose) contains: escherichia coli fimbrial adhesin f4ab f4ac f5 f6 %65% er60 278% er70 279% er 50 >80% er35 >55% er 70 >35% er25 >50% er120 e. coli lt enterotoxoid clotridium perfringens (type c) btoxoid clostridium novyi (type b) a toxoid % erx: percentage of immunized rabbits with enzyme immunoassay response. suspension for injection (im)

hipra philippines inc.; distributor: hipra philippines inc. - inactivated escherichia coli fimbrial adhesin (f4ab, f4ac, f5 and f6) , heat labile (lt) enterotoxoid , clotridium perfringens (type c) b toxoid , clostridium novyi (type b) a toxoid vaccine (vet.) - suspension for injection (im) - each 2 ml (dose) contains: escherichia coli fimbrial adhesin f4ab f4ac f5 f6 %65% er60 278% er70 279% er 50 >80% er35 >55% er 70 >35% er25 >50% er120 e. coli lt enterotoxoid clotridium perfringens (type c) btoxoid clostridium novyi (type b) a toxoid % erx: percentage of immunized rabbits with enzyme immunoassay response.